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bone mass. Interestingly, focal osteosclerosis accom-
panies global osteoporosis in TSHR/ mice. These ar-
eas of dense bone have histological features indicating
rapid formation. Thus, TSH appears to affect both osteo-
blasts and osteoclasts.TSH, The Bone Suppressing
Because a role for TSH in bone remodeling was notHormone
predicted, expression of TSHRs in bone cells had not
previously been examined. The present authors, how-
ever, convincingly demonstrate expression of TSHRs on
the surface of both osteoblast and osteoclast precur-The skeleton is a dynamic organ whose structural in-
sors, in vivo and in vitro. They document suppressivetegrity depends on constant remodeling, controlled by
effects of TSH on osteoclast and osteoblast differentia-many local and systemic factors. In this issue of Cell,
tion, and enhanced maturation of cells lacking TSHR.Abe et al. (2003) identify thyroid-stimulating hormone
Therefore, unlike thyroid hormone, which acts directly(TSH) as an important regulator of this process.
only on osteoblasts, TSH suppresses the function of
both osteoblasts and osteoclasts in a cell autonomousThyroid disease and osteoporosis are prevalent in the
fashion. In mice unable to respond to TSH due to ab-elderly, and von Recklinghausen recognized over 100
sence of the receptor, the result is a high turnover stateyears ago that hyperthyroidism can cause osteoporosis.
in which bone resorption outpaces bone formation (Fig-Increased circulating thyroid hormone induces a high
ure 1).turnover state in bone, with increased activity by osteo-
Osteoblast differentiation requires expression of theblasts and osteoclasts. The resorptive activity of osteo-
transcription factors Runx-2 and osterix, but is also influ-clasts, however, predominates, eventuating in decreased
enced by the Wnt pathway (especially via the coreceptorstructural integrity of the skeleton (Greenspan and
LRP-5) and activation of Flk-1, a VEGF receptor (Karse-Greenspan, 1999). Thus far, investigators have focused
nty and Wagner, 2002). TSH suppresses expression ofon the direct effects of active thyroid hormone (triiodo-
LRP-5 and Flk-1, but does not affect Runx-2 or osterix.thyronine, T3) on bone cells, via thyroid hormone recep-
Osteoblasts influence osteoclast differentiation in vivotors (TR1 and TR), members of the nuclear hormone
via their expression of RANKL and M-CSF (Teitelbaumreceptor family that induce transcription in a ligand-
and Ross, 2003). The enhanced osteoclastogenesis ofdependent manner (Britto et al., 1994). Osteoblasts ex-
TSHR/ mice cannot be attributed to enhanced expres-
press TRs and respond to T3 with increased proliferation
sion of either M-CSF or RANKL, indicating that this is
and expression of lineage-specific markers such as al-
not the point at which osteoclast and osteoblast activity
kaline phosphatase, osteocalcin, and collagen. Interest-
becomes uncoupled. Instead, the mutant animals have
ingly, although osteoclasts have TRs, their response to increased levels of TNF, a cytokine that synergizes
T3 appears to be mediated entirely by osteoblasts. In with RANKL in the osteoclastogenic process.
the presence of vitamin D3, T3 induces osteoblasts to RANKL activates a number of signaling pathways in
express of RANK ligand (RANKL), the key osteoclasto- osteoclasts, including NF-B and the MAPKs (JNK, ERK,
genic cytokine. Additionally, mice lacking the known and p38). Osteoclast precursors lacking one or both
active isoforms of TRs have retarded bone growth and copies of the TSHR gene exhibit increased signaling
maturation, but do not manifest increased bone mineral through JNK and NF-B, but not ERK or p38. Likewise,
density, as would be predicted if, in fact, T3 is an impor- coadministration of TSH with RANKL in wild-type osteo-
tant stimulus of bone resorption in vivo (Gothe et al., clast cultures inhibits NF-B and JNK. Thus, TSH arrests
1999). osteoclast differentiation through defined pathways
A previously unexplored consequence of hyperthy- downstream of RANKL.
roidism is suppression of thyroid stimulating hormone Perhaps the most intriguing issue posed by the dis-
(TSH), which is produced by the anterior pituitary and covery of this new regulator of skeletal remodeling is
directly controls production and release of thyroid hor- the mechanism by which TSH exerts its effects. The
mones by thyroid follicles. The TSH receptor (TSHR) is TSHR is a member of the seven transmembrane G pro-
a seven transmembrane glycosylated G protein-coupled tein-coupled receptor family that also includes the calci-
protein expressed by many tissues beyond the thyroid tonin and parathyroid hormone (PTH) receptors, both
(Davies et al., 2002). Although several extrathyroidal regulators of bone turnover. Although the calcitonin re-
functions for TSH have been proposed, evidence sup- ceptor is expressed on both osteoclasts and osteo-
porting this contention is scant. In this issue of Cell, Abe blasts, its primary function is inhibition of bone resorp-
et al. (2003) demonstrate a critical role for TSH in skeletal tion, decreasing osteoclast motility and secretion, by
remodeling that is independent of its effects on circulat- osteoclasts, of acid and proteases (Samura et al., 2000).
ing thyroid hormone. Using mice in which the TSHR The PTH receptor is highly expressed only on osteo-
gene is replaced by GFP, they find bone mineral density, blasts, which PTH impacts in a biphasic manner (Locklin
et al., 2003). Specifically, intermittent administration ofin face of normal levels of thyroid hormone, depends
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Figure 1. Bone Turnover Is Enhanced in the
Absence of TSHR
In normal cells, TSH inhibits the differentia-
tion of both osteoblast and osteoclast precur-
sors. In TSHR/ mice, this inhibition is re-
moved. Osteoblast precursors upregulate
LRP-5 and FLK-1, leading to increased num-
bers of differentiated osteoblasts (OB) and
increased new bone formation. Production of
TNF is also increased, and this cytokine
enhances the differentiation of osteoclast
precursors. In the absence of the TSHR,
osteoclast precursors show enhanced RANKL-
mediated differentiation, with increased phos-
phorylation of JNK (JNK-p) and activation of
NF-B. The net result is a marked increase
in mature osteoclasts (OC) with concomitant
bone resorption that outpaces new bone
formation. Thus, TSHR/ mice are osteopo-
rotic.
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The Double Life of RibosomalIn recent years, genetic targeting of a number of pro-
teins, including c-src, leptin, and TSHR, have yielded Proteins
unexpected bone phenotypes. In retrospect, the discov-
ery of TSH as an important player in bone homeostasis
should perhaps not be so surprising, given its relation-
Many integral proteins of the ribosome also carry outship to other critical mediators of bone cell function.
extra-ribosomal functions as independent polypep-Nevertheless, the connection would not likely have been
tides, raising questions as to their evolutionary deriva-made without the use of gene-ablated mice. The contin-
tion. In this issue of Cell, Mazumder et al. report aued generation of mutant mice, and the examination of
surprising new twist in the dual life of these molecules:their bones, will provide many additional regulators of
as part of a cellular response to interferon, a large-bone homeostasis in the years to come.
subunit protein dramatically exits the ribosome to bind
and inhibit the translation of a specific mRNA.
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total ribosome mass and efficient translation cannot
take place without them. In bacteria, however, the ab-
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